context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
and $ 131 million, respectively. | text | 131 | monetaryItemType | text: <entity> 131 </entity> <entity type> monetaryItemType </entity type> <context> and $ 131 million, respectively. </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
16 additional SHOP facilities for $ 230 million | text | 230 | monetaryItemType | text: <entity> 230 </entity> <entity type> monetaryItemType </entity type> <context> 16 additional SHOP facilities for $ 230 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. | text | 102 | monetaryItemType | text: <entity> 102 </entity> <entity type> monetaryItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. | text | 11 | percentItemType | text: <entity> 11 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. | text | 6.0 | percentItemType | text: <entity> 6.0 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. | text | 7.0 | percentItemType | text: <entity> 7.0 </entity> <entity type> percentItemType </entity type> <context> in January 2021, the Company provided the buyer with financing of $ 150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer’s equity ownership in each property. Upon maturity in January 2023, the borrower did not make the required principal repayment. In February 2023, the borrower made a partial principal repayment of $ 102 million, and the remaining balance owed was refinanced with the Company. In connection with the refinance, the maturity date of the loan was extended to January 2024 and the interest rate on the loan was increased to a variable rate based on Term SOFR (plus an 11 basis point adjustment related to SOFR transition) plus 6.0 % for the first six months of the extended term, increasing to 7.0 % for the last six months of the extended term. The Company also received a $ 1 million extension fee in connection with the refinance, which was recognized in interest income through the maturity date of January 2024. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million | text | 674 | monetaryItemType | text: <entity> 674 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with the sale of 59 outpatient medical buildings for $ 674 million in July 2024 and the 2 outpatient medical buildings for $ 23 million in November 2024 (see Note 5), the Company provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million and $ 14 million, respectively. The remainder of the sales price was received in cash at the time of sales. The seller financing has an initial term that matures in July 2026 and includes two 12-month extension options. The interest rate on the seller financing is fixed at 6.0 % for the initial term and increases to 6.5 % during the optional extension periods. The Company also received a $ 1 million loan origination fee in connection with the loan, which is being recognized in interest income over the remaining term of the loan. In connection with this seller financing, the Company reduced the gain on sales of real estate and recognized a mark-to-market discount of $ 21 million during the year ended December 31, 2024. This discount is based on the difference between the stated interest rate and the corresponding prevailing market rate as of the transaction date. The discount is recognized as interest income over the term of the discounted loan using the effective interest rate method. During the year ended December 31, 2024, the Company recognized $ 3 million </context> | us-gaap:ProceedsFromLoanOriginations1 |
In January 2025, the Company received full repayment of the outstanding balance of one $ 15 million secured loan with an original maturity of July 2027. As a result of this repayment, the $ 85 million of remaining commitments as of December 31, 2024 to fund additional loans for outpatient medical capital expenditure projects was reduced to $ 67 million. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> In January 2025, the Company received full repayment of the outstanding balance of one $ 15 million secured loan with an original maturity of July 2027. As a result of this repayment, the $ 85 million of remaining commitments as of December 31, 2024 to fund additional loans for outpatient medical capital expenditure projects was reduced to $ 67 million. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In February 2023, the Company received full repayment of the outstanding balance of one $ 35 million secured loan. | text | 35 | monetaryItemType | text: <entity> 35 </entity> <entity type> monetaryItemType </entity type> <context> In February 2023, the Company received full repayment of the outstanding balance of one $ 35 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In April 2023, the Company received full repayment of the outstanding balance of one $ 14 million secured loan. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> In April 2023, the Company received full repayment of the outstanding balance of one $ 14 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In May 2023, the Company received full repayment of two outstanding secured loans with an aggregate balance of $ 12 million. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company received full repayment of two outstanding secured loans with an aggregate balance of $ 12 million. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
Also in May 2023, the interest rate on one secured loan with an outstanding balance of $ 21 million was converted from a variable rate based on LIBOR to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition). In October 2023, the Company received full repayment of the outstanding balance of this $ 21 million secured loan. | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> Also in May 2023, the interest rate on one secured loan with an outstanding balance of $ 21 million was converted from a variable rate based on LIBOR to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition). In October 2023, the Company received full repayment of the outstanding balance of this $ 21 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In May 2022, the Company received full repayment of the outstanding balance of one $ 2 million secured loan. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> In May 2022, the Company received full repayment of the outstanding balance of one $ 2 million secured loan. </context> | us-gaap:ProceedsFromCollectionOfFinanceReceivables |
In November 2022, the Company received full repayment of the outstanding balance of one $ 1 million mezzanine loan. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company received full repayment of the outstanding balance of one $ 1 million mezzanine loan. </context> | us-gaap:ProceedsFromCollectionOfFinanceReceivables |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. | text | 8.5 | percentItemType | text: <entity> 8.5 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. | text | 10.5 | percentItemType | text: <entity> 10.5 </entity> <entity type> percentItemType </entity type> <context> In December 2022, the Company extended the maturity dates of four secured loans with an aggregate outstanding balance of $ 61 million, originally scheduled to mature in December 2022, by one year to December 2023. In connection with the extensions, the interest rates on the loans were increased to a variable rate based on Term SOFR (plus a 10 basis point adjustment related to SOFR transition) with a floor of 8.5 % for the first six months of the extended term, increasing to a floor of 10.5 % for the last six months of the extended term. All four of these secured loans were repaid during 2023 as discussed above. </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the resident’s previous home. At December 31, 2024 and 2023, the Company held $ 61 million | text | 61 | monetaryItemType | text: <entity> 61 </entity> <entity type> monetaryItemType </entity type> <context> For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the resident’s previous home. At December 31, 2024 and 2023, the Company held $ 61 million </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
and $ 43 million, respectively, of such notes receivable. | text | 43 | monetaryItemType | text: <entity> 43 </entity> <entity type> monetaryItemType </entity type> <context> and $ 43 million, respectively, of such notes receivable. </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70 % ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 70 | percentItemType | text: <entity> 70 </entity> <entity type> percentItemType </entity type> <context> unconsolidated lab joint ventures in South San Francisco, California in which the Company holds a 70 % ownership percentage in each joint venture. These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 20 | percentItemType | text: <entity> 20 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 67 | percentItemType | text: <entity> 67 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 80 | percentItemType | text: <entity> 80 </entity> <entity type> percentItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:NumberOfRealEstateProperties |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:NumberOfRealEstateProperties |
Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Includes two unconsolidated outpatient medical joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV ( 20 %) and (ii) Suburban Properties, LLC ( 67 %). In April 2023, the Company acquired the remaining 80 % interest in one of the two properties that were in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 4). These joint ventures have been aggregated herein due to similarity of the investments and operations. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
$ 49 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint ventures and capitalized interest related to the redevelopment activities at the South San Francisco JVs. The differences are amortized over the remaining useful lives of the related assets and are included in equity income (loss) from unconsolidated joint ventures. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> $ 49 million, respectively, is primarily attributable to the difference between the amount for which the Company purchased its interest in certain joint ventures and the historical carrying value of the net assets of the related joint ventures and capitalized interest related to the redevelopment activities at the South San Francisco JVs. The differences are amortized over the remaining useful lives of the related assets and are included in equity income (loss) from unconsolidated joint ventures. </context> | us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. | text | 30 | percentItemType | text: <entity> 30 </entity> <entity type> percentItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. | text | seven | integerItemType | text: <entity> seven </entity> <entity type> integerItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. </context> | us-gaap:NumberOfRealEstateProperties |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. | text | 126 | monetaryItemType | text: <entity> 126 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. </context> | us-gaap:ProceedsFromRealEstateAndRealEstateJointVentures |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. | text | 70 | percentItemType | text: <entity> 70 </entity> <entity type> percentItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. | text | 311 | monetaryItemType | text: <entity> 311 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company sold a 30 % interest in seven lab buildings in South San Francisco, California to a sovereign wealth fund (“SWF Partner”) for cash of $ 126 million. Following this transaction, the Company and the SWF Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 70 % investment in the South San Francisco joint ventures (the “South San Francisco JVs”) at fair value, and accounting for its investment using the equity method. The fair values of the Company’s retained investment were based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2022, the Company recognized a gain upon change of control of $ 311 million, which is recorded in other income (expense), net. </context> | us-gaap:DeconsolidationGainOrLossAmount |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. | text | 65 | percentItemType | text: <entity> 65 </entity> <entity type> percentItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. </context> | us-gaap:NumberOfRealEstateProperties |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. </context> | us-gaap:ProceedsFromRealEstateAndRealEstateJointVentures |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. | text | 35 | percentItemType | text: <entity> 35 </entity> <entity type> percentItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. | text | 78 | monetaryItemType | text: <entity> 78 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, the Company sold a 65 % interest in two lab buildings in San Diego, California (the “Callan Ridge JV”) to a third-party (the “JV Partner”) for net proceeds of $ 128 million. Following the transaction, the Company and the JV Partner share in key decisions of the assets through their voting rights, resulting in the Company deconsolidating the assets, recognizing its retained 35 % investment in the Callan Ridge JV at fair value, and accounting for its investment using the equity method. The fair value of the Company’s retained investment was based on a market approach, utilizing an agreed-upon contractual sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. During the year ended December 31, 2024, the Company recognized a gain upon change of control of $ 78 million, which is recorded in other income (expense), net. </context> | us-gaap:DeconsolidationGainOrLossAmount |
On the Closing Date of the Merger, the Company acquired intangible assets of $ 891 million, inclusive of $ 852 million of lease-up intangibles and $ 39 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of $ 150 million | text | 891 | monetaryItemType | text: <entity> 891 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date of the Merger, the Company acquired intangible assets of $ 891 million, inclusive of $ 852 million of lease-up intangibles and $ 39 million of above market lease intangibles. Also on the Closing Date of the Merger, the Company assumed intangible liabilities of $ 150 million </context> | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
During the year ended December 31, 2023, in conjunction with the Company’s acquisition of real estate, the Company acquired $ 0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, in conjunction with the Company’s acquisition of real estate, the Company acquired $ 0.5 million of intangible assets with a weighted average amortization period at acquisition of 5 years. </context> | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of $ 51 million, | text | 51 | monetaryItemType | text: <entity> 51 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date of the Merger, inclusive of measurement period adjustments, the Company recognized goodwill of $ 51 million, </context> | us-gaap:Goodwill |
On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of $ 400 million (the “2028 Term Loan”) that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as borrower, and the other parties thereto. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, upon the consummation of the Merger, the Company assumed senior unsecured term loans in an aggregate principal amount of $ 400 million (the “2028 Term Loan”) that mature in May 2028 (see Note 3) pursuant to an amendment to a term loan agreement originally executed by the Physicians Partnership, as borrower, and the other parties thereto. DOC DR OP Sub is the borrower under, and the Company, Healthpeak OP, and DOC DR Holdco are guarantors of, the 2028 Term Loan. </context> | us-gaap:DebtInstrumentFaceAmount |
In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub’s credit ratings as of December 31, 2024, the 2028 Term Loan had a blended fixed effective interest rate of | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> In connection with the assumption of the 2028 Term Loan, the Company acquired three related interest rate swap instruments that were redesignated as cash flow hedges as of the Closing Date. The 2028 Term Loan associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on DOC DR OP Sub’s credit ratings as of December 31, 2024, the 2028 Term Loan had a blended fixed effective interest rate of </context> | us-gaap:NumberOfInterestRateDerivativesHeld |
4.44 %, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments. | text | 4.44 | percentItemType | text: <entity> 4.44 </entity> <entity type> percentItemType </entity type> <context> 4.44 %, inclusive of the impact of these interest rate swap instruments and amortization of the related premium. See also Note 22 for a discussion of the impact of the related interest rate swap instruments. </context> | us-gaap:DebtInstrumentInterestRateEffectivePercentage |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was | text | 0.85 | percentItemType | text: <entity> 0.85 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was | text | 1.65 | percentItemType | text: <entity> 1.65 </entity> <entity type> percentItemType </entity type> <context> Loans outstanding under the 2028 Term Loan bear interest at an annual rate equal to (i) the applicable margin, plus (ii) Daily SOFR (plus a 10 basis point adjustment related to SOFR transition). The applicable margin under the 2028 Term Loan ranges from 0.85 % to 1.65 % for Daily SOFR loans and is based on the credit ratings of DOC DR OP Sub. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of the adjustment related to SOFR transition, the margin on the 2028 Term Loan was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 4.30 | percentItemType | text: <entity> 4.30 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 3.95 | percentItemType | text: <entity> 3.95 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentFaceAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. | text | 2.63 | percentItemType | text: <entity> 2.63 </entity> <entity type> percentItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, DOC DR OP Sub assumed, and the Company and Healthpeak OP guaranteed, Physicians Partnership’s $ 1.25 billion aggregate principal of senior unsecured notes (see Note 3), including: (i) $ 400 million aggregate principal amount of 4.30 % senior unsecured notes due 2027, (ii) $ 350 million aggregate principal amount of 3.95 % senior unsecured notes due 2028, and (iii) $ 500 million aggregate principal amount of 2.63 % senior unsecured notes due 2031. On the Closing Date, the Company capitalized $ 1 million of costs paid to the bondholders, which are being amortized into interest expense on the Consolidated Statements of Operations over the terms of the related senior unsecured notes. The senior unsecured notes contain certain covenants that are consistent with Healthpeak OP’s previously issued senior unsecured notes, as further described below. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed $ 128 million aggregate principal of mortgage debt (see Note 3), which was secured by | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> Lastly, on March 1, 2024, concurrently with the consummation of the Merger, the Company assumed $ 128 million aggregate principal of mortgage debt (see Note 3), which was secured by </context> | us-gaap:DebtInstrumentFaceAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | five | integerItemType | text: <entity> five </entity> <entity type> integerItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:NumberOfRealEstateProperties |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 259 | monetaryItemType | text: <entity> 259 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:DebtInstrumentCollateralAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 128 | monetaryItemType | text: <entity> 128 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:DebtInstrumentFaceAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 59 | monetaryItemType | text: <entity> 59 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:DebtInstrumentPeriodicPaymentInterest |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 3.77 | percentItemType | text: <entity> 3.77 </entity> <entity type> percentItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:LongTermDebtPercentageBearingFixedInterestRate |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:LongtermDebtPercentageBearingVariableInterestAmount |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 7.25 | percentItemType | text: <entity> 7.25 </entity> <entity type> percentItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:LongTermDebtPercentageBearingVariableInterestRate |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet |
five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> five outpatient medical buildings, with an aggregate carrying value of $ 259 million as of March 1, 2024. Of this $ 128 million, $ 59 million was fixed rate debt with a weighted average contractual interest rate of 3.77 % and maturities ranging from November 2024 through December 2026 and $ 69 million was variable rate debt with a weighted average contractual interest rate of 7.25 % and maturities ranging from December 2026 through November 2028. The Company recognized a net discount of $ 0.5 million on the $ 128 million aggregate principal of mortgage debt assumed on the Closing Date, which is being amortized into interest expense on the Consolidated Statements of Operations using the effective interest rate method. The Company acquired one </context> | us-gaap:NumberOfInterestRateDerivativesHeld |
related interest rate swap instrument with a notional amount of $ 36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> related interest rate swap instrument with a notional amount of $ 36 million of variable rate mortgage debt that was redesignated as a cash flow hedge as of the Closing Date (see Note 22), which matured in October 2024. </context> | us-gaap:DebtInstrumentFaceAmount |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was | text | 10 | percentItemType | text: <entity> 10 </entity> <entity type> percentItemType </entity type> <context> On May 23, 2019, the Company executed a $ 2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $ 2.5 billion to $ 3.0 billion and extend the maturity date to January 20, 2026 with two six-month extension options, subject to certain customary conditions. On February 10, 2023, the Company executed an amendment to the Revolving Facility to convert the interest rate benchmark from LIBOR to SOFR. On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Revolving Facility to, among other things, join DOC DR Holdco and DOC DR OP Sub as guarantors of Healthpeak OP’s obligations under the Revolving Facility. In December 2024, the Company amended and restated its Revolving Facility to extend the maturity date to January 19, 2029. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at the applicable interest rate benchmark plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at December 31, 2024, and inclusive of a 10 basis point adjustment related to SOFR transition, the margin on the Revolving Facility was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
0.88 % and the facility fee was | text | 0.88 | percentItemType | text: <entity> 0.88 </entity> <entity type> percentItemType </entity type> <context> 0.88 % and the facility fee was </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
0.15 %. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $ 750 million, subject to securing additional commitments. At each of December 31, 2024 and 2023, the Company had no balance outstanding under the Revolving Facility. | text | 0.15 | percentItemType | text: <entity> 0.15 </entity> <entity type> percentItemType </entity type> <context> 0.15 %. The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $ 750 million, subject to securing additional commitments. At each of December 31, 2024 and 2023, the Company had no balance outstanding under the Revolving Facility. </context> | us-gaap:LineOfCreditFacilityCommitmentFeePercentage |
On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be drawn from time to time during a 180 -day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the $ 500 million under the 2027 Term Loans in October 2022. $ 250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other $ 250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be drawn from time to time during a 180 -day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the $ 500 million under the 2027 Term Loans in October 2022. $ 250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other $ 250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend. </context> | us-gaap:DebtInstrumentFaceAmount |
On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be drawn from time to time during a 180 -day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the $ 500 million under the 2027 Term Loans in October 2022. $ 250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other $ 250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend. | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> On August 22, 2022, the Company executed a term loan agreement (as amended or modified as described herein, the “Term Loan Agreement”) that provided for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $ 500 million (the “2027 Term Loans”). The 2027 Term Loans were available to be drawn from time to time during a 180 -day period after closing, subject to customary borrowing conditions, and the Company drew the entirety of the $ 500 million under the 2027 Term Loans in October 2022. $ 250 million of the 2027 Term Loans have an initial stated maturity of 4.5 years, which may be extended for a one-year period subject to certain customary conditions. The other $ 250 million of the 2027 Term Loans has a stated maturity of five years with no option to extend. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01 % based on the Company’s achievement of specified sustainability-linked metrics. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of achievement of a sustainability-linked metric and an adjustment related to SOFR transition, the margin on the 2027 Term Loans was 0.94 %. | text | 0.94 | percentItemType | text: <entity> 0.94 </entity> <entity type> percentItemType </entity type> <context> SOFR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The 2027 Term Loans also include a sustainability-linked pricing component whereby the applicable margin under the 2027 Term Loans may be reduced by 0.01 % based on the Company’s achievement of specified sustainability-linked metrics. Based on the Company’s credit ratings as of December 31, 2024, and inclusive of achievement of a sustainability-linked metric and an adjustment related to SOFR transition, the margin on the 2027 Term Loans was 0.94 %. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of December 31, 2024, the 2027 Term Loans had a blended fixed effective interest rate of 3.76 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of December 31, 2024, the 2027 Term Loans had a blended fixed effective interest rate of 3.76 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. </context> | us-gaap:NumberOfInterestRateDerivativesHeld |
In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of December 31, 2024, the 2027 Term Loans had a blended fixed effective interest rate of 3.76 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. | text | 3.76 | percentItemType | text: <entity> 3.76 </entity> <entity type> percentItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments that are designated as cash flow hedges (see Note 22). The 2027 Term Loans associated with these interest rate swap instruments are reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instruments. Based on the Company’s credit ratings as of December 31, 2024, the 2027 Term Loans had a blended fixed effective interest rate of 3.76 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. </context> | us-gaap:DerivativeFixedInterestRate |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2024, concurrently with the consummation of the Merger, the Company executed an amendment to the Term Loan Agreement pursuant to which (i) the maximum incremental borrowing capacity under the Term Loan Agreement was increased from $ 1.0 billion to $ 1.5 billion, subject to securing additional commitments, (ii) the Company borrowed senior unsecured term loans in an aggregate principal amount of $ 750 million with a stated maturity of five years (the “2029 Term Loan”), and (iii) DOC DR Holdco and DOC DR OP Sub were joined as guarantors of Healthpeak OP’s obligations under the Term Loan Agreement. As of December 31, 2024, the unused borrowing capacity under the Term Loan Agreement was </context> | us-gaap:DebtInstrumentFaceAmount |
4.66 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. | text | 4.66 | percentItemType | text: <entity> 4.66 </entity> <entity type> percentItemType </entity type> <context> 4.66 %, inclusive of the impact of these interest rate swap instruments and amortization of the related debt issuance costs. </context> | us-gaap:DebtInstrumentInterestRateEffectivePercentage |
At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. </context> | us-gaap:LineOfCredit |
At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had $ 1.25 billion and $ 500 million, respectively, of loans outstanding under the Term Loan Agreement. </context> | us-gaap:LineOfCredit |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. | text | 150 | monetaryItemType | text: <entity> 150 </entity> <entity type> monetaryItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. </context> | us-gaap:ShortTermBorrowings |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. | text | 4.65 | percentItemType | text: <entity> 4.65 </entity> <entity type> percentItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. </context> | us-gaap:DebtWeightedAverageInterestRate |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. | text | 720 | monetaryItemType | text: <entity> 720 </entity> <entity type> monetaryItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. </context> | us-gaap:ShortTermBorrowings |
In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. | text | 5.70 | percentItemType | text: <entity> 5.70 </entity> <entity type> percentItemType </entity type> <context> In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, short-term unsecured notes with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At each of December 31, 2024 and 2023, the maximum aggregate face or principal amount that could be outstanding at any one time was $ 2.0 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of short-term unsecured notes issued under the Commercial Paper Program. During each of the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 9 million of interest expense related to fees and amortization of debt issuance costs related to its Commercial Paper Program and Revolving Facility. At December 31, 2024, the Company had $ 150 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 25 days and a weighted average interest rate of 4.65 %. At December 31, 2023, the Company had $ 720 million of notes outstanding under the Commercial Paper Program, with original maturities of approximately 37 days and a weighted average interest rate of 5.70 %. </context> | us-gaap:DebtWeightedAverageInterestRate |
At December 31, 2024 and 2023, the Company had senior unsecured notes outstanding with an aggregate principal balance of $ 6.7 billion | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the Company had senior unsecured notes outstanding with an aggregate principal balance of $ 6.7 billion </context> | us-gaap:DebtInstrumentCarryingAmount |
and $ 5.5 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at December 31, 2024. | text | 5.5 | monetaryItemType | text: <entity> 5.5 </entity> <entity type> monetaryItemType </entity type> <context> and $ 5.5 billion, respectively. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions, and other customary terms. The Company believes it was in compliance with these covenants at December 31, 2024. </context> | us-gaap:DebtInstrumentCarryingAmount |
During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed $ 1.25 billion aggregate principal of senior unsecured notes. | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, there were no issuances, repurchases, or redemptions of senior unsecured notes; however, as described above, concurrently with the consummation of the Merger, the Company assumed $ 1.25 billion aggregate principal of senior unsecured notes. </context> | us-gaap:DebtInstrumentFaceAmount |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. </context> | us-gaap:DebtInstrumentFaceAmount |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 5.25 | percentItemType | text: <entity> 5.25 </entity> <entity type> percentItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In May 2023, the Company issued $ 350 million of 5.25 % senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $ 400 million of senior unsecured notes due 2032 issued in January 2023. </context> | us-gaap:DebtInstrumentFaceAmount |
In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. | text | 348 | monetaryItemType | text: <entity> 348 </entity> <entity type> monetaryItemType </entity type> <context> In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. </context> | us-gaap:RepaymentsOfDebt |
In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. | text | 3.40 | percentItemType | text: <entity> 3.40 </entity> <entity type> percentItemType </entity type> <context> In February 2025, the Company repaid $ 348 million aggregate principal amount of 3.40 % senior unsecured notes at maturity. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 356 | monetaryItemType | text: <entity> 356 </entity> <entity type> monetaryItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:DebtInstrumentCarryingAmount |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 255 | monetaryItemType | text: <entity> 255 </entity> <entity type> monetaryItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:DebtInstrumentCarryingAmount |
$ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 | text | 19 | integerItemType | text: <entity> 19 </entity> <entity type> integerItemType </entity type> <context> $ 356 million and $ 255 million, respectively, in aggregate principal of mortgage debt outstanding. At December 31, 2024, this mortgage debt was secured by 19 </context> | us-gaap:NumberOfRealEstateProperties |
outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of | text | 2 | integerItemType | text: <entity> 2 </entity> <entity type> integerItemType </entity type> <context> outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of </context> | us-gaap:NumberOfRealEstateProperties |
At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. | text | 15 | integerItemType | text: <entity> 15 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. </context> | us-gaap:NumberOfRealEstateProperties |
At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. | text | 2 | integerItemType | text: <entity> 2 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023, this mortgage debt was secured by 15 outpatient medical buildings and 2 CCRCs, with an aggregate carrying value of $ 587 million. </context> | us-gaap:NumberOfRealEstateProperties |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.